Hosted on MSN1mon
Sana Biotech Stock Triples After Type 1 Diabetes Trial Wows Analysts: Retail Erupts In ExcitementSana Biotechnology Inc.'s stock soared over 200% on Wednesday ... analyst reactions to initial data from a groundbreaking type 1 diabetes trial using Sana's experimental cell therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback